ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07939997. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CLEAR-ESO: ctDNA CLEARance to Predict Successful Non-operative Management and Pathologic Complete Response in ESOphageal Squamous Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment. Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance. The main questions this study aims to answer are: * Can ctDNA clearance after chemoradiotherapy predict 2-year complete response-disease-free survival? * Can ctDNA clearance improve the prediction of durable complete response compared with standard response assessment methods, including PET/CT and endoscopy? * Can ctDNA clearance at different timepoints during and after chemoradiotherapy help identify patients at risk of disease recurrence? The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care. Study participants will: * Provide blood samples at baseline, during Week 3 of chemoradiotherapy, and at completion of chemoradiotherapy for ctDNA analysis. * Participate in one of two observational cohorts. Participants in the Longitudinal ctDNA Cohort will provide additional blood samples at 6 weeks and 3 months after chemoradiotherapy and every 3 months through 24 months. Participants in the Limited-Sampling Research Cohort will provide only three protocol-required blood samples. * Continue standard-of-care cancer treatment and follow-up according to treating physician discretion. * Allow researchers to review medical records to assess treatment response, cancer recurrence, salvage therapy, and survival status through 24 months after completion of chemoradiotherapy. Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort. This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.
Study identification
- NCT ID
- NCT07939997
- Recruitment status
- Not yet recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay) Diagnostic Test
Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2027 (Estimated)
- Primary completion
- Aug 24, 2030 (Estimated)
- Completion
- Aug 2031 (Estimated)
- Last update posted
- Nov 16, 2026
2027 – 2031
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07939997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.